Consensus Zai Lab Limited

Stocks

ZLAB

US98887Q1040

Pharmaceuticals

Market Closed - Nasdaq 01:30:00 27/08/2026 am IST			5-day change	1st Jan Change
26.03 ^USD	-0.53%		-2.58%	+47.56%

26/08	Zai Lab's Net Loss Widens 14% in H1, Revenue Drops 6%	MT
25/08	Asian Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading	MT

Evolution of the Average Target: Zai Lab Limited

Evolution of the Target Price: Zai Lab Limited

Changes in Analyst Recommendations: Zai Lab Limited

e89e76c4a.6BBs60yOjnQ4NmzajOoL0TkJhXe7v1MEugW3cyWSRS0.p0EriTv2oz1wfRqYu9x_lXIw9xnU3QR14lf2MET9D3vRcyKRKsjGRHZcAw~b65328052196a656ea05c830c65a98ce

Analysts' recommendations: Zai Lab Limited

07/01	UBS Initiates Zai Lab at Buy With $35 Price Target	MT
05/11	Zai Lab updates on Amgen's bemarituzumab Phase 1B/3 Fortitude-102 study	RE
05/11	Zai Lab Limited Announces Update on Amgen's Bemarituzumab Phase 1B/3 Fortuda-102 Study	CI
13/25/13	JPMorgan Adjusts Price Target on Zai Lab to $51 From $44, Keeps Overweight Rating	MT
03/25/03	BofA Securities Downgrades Zai Lab to Neutral	MT
12/24/12	JPMorgan Cuts Price Target on Zai Lab to $38 From $43, Maintains Overweight Rating	MT
14/23/14	Morgan Stanley Starts Coverage on Zai Lab with Overweight Rating, $47.50 Price Target	MT
26/23/26	Citigroup Adjusts Price Target on Zai Lab to $128 From $130, Maintains Buy Rating	MT
26/23/26	Goldman Sachs Lowers Price Target on Zai Lab to $73.34 From $82.47, Maintains Buy Rating	MT
10/23/10	Cantor Fitzgerald Initiates Coverage on Zai Lab With Overweight Rating, $70 Price Target	MT
12/23/12	BofA Adjusts Price Target on Zai Lab to $62.50 From $75, Maintains Buy Rating	MT
11/23/11	Citigroup Adjusts Price Target on Zai Lab to $130 From $138, Keeps Buy Rating	MT
16/23/16	JPMorgan Adjusts Price Target on Zai Lab to $70 From $79, Maintains Overweight Rating	MT
18/22/18	JPMorgan Chase Lowers Price Target on Zai Lab to $79 From $96, Maintains Overweight Rating	MT
11/22/11	Citigroup Adjusts Price Target on Zai Lab to $127 From $199, Maintains Buy Rating	MT
09/22/09	Citigroup Adjusts Zai Lab's Price Target to $199 From $193, Reiterates Buy Rating	MT
26/22/26	CSPC Pharma Shares Fall After Weaker 1Q Profit	DJ
12/22/12	Citigroup Adjusts Zai Lab Price Target to $193 From $198, Maintains Buy Rating	MT
11/22/11	SVB Securities Adjusts Zai Lab Price Target to $95 From $101, Maintains Outperform Rating	MT
06/22/06	Guggenheim Adjusts Price Target for Zai Lab to $85 From $134, Maintains Buy Rating	MT
21/22/21	SVB Leerink Adjusts Zai Lab Price Target to $101 From $102, Maintains Outperform Rating	MT
04/22/04	JPMorgan Lowers Zai Lab's Price Target to $112 From $136, Maintains Overweight Rating	MT
03/22/03	Analyst recommendations: Acushnet, Bristol-Myers Squibb, Intel, iQIYI, Polymetal...
03/22/03	SVB Leerink Adjusts Zai Lab Price Target to $102 From $194, Maintains Outperform Rating	MT
04/21/04	Citigroup Raises Price Target for Zai Lab to $231 From $217, Maintains Buy Rating	MT

More recommendations

Biopharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ZAI LAB LIMITED					+27.31%
	REGENERON PHARMACEUTICALS, INC.					+3.15%
	MODERNA, INC.					-30.16%
	CSL LIMITED					-5.41%
	SAMSUNG BIOLOGICS CO.,LTD.					+23.09%
	UCB					+29.08%
	BIOGEN INC.					+6.85%
	INCYTE CORPORATION					-0.78%
	INNOVENT BIOLOGICS, INC.					+15.15%
	SWEDISH ORPHAN BIOVITRUM AB					+7.19%
	Average					+7.55%
	Weighted average by Cap.					+3.86%